A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: HR+ Metastatic Breast Cancer|Breast Cancer|Breast Cancer Metastatic
Interventions: DRUG: GMI-1359
Sponsor: GlycoMimetics Incorporated